| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/16/2001 | WO2001058449A1 Water dispersible formulation of paroxetine |
| 08/16/2001 | WO2001058448A1 Apoptosis inhibitor |
| 08/16/2001 | WO2001058447A1 Controlled-release compositions containing opioid agonist and antagonist |
| 08/16/2001 | WO2001058446A1 Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers |
| 08/16/2001 | WO2001058445A1 Therapy with cannabinoids in the treatment of cerebral tumor |
| 08/16/2001 | WO2001058444A1 Use of cyp1b1 inhibitors for treating cancer |
| 08/16/2001 | WO2001058443A1 TNF- α INHIBITORS |
| 08/16/2001 | WO2001058442A1 An essential constituent and method of use for maintaining hair coloration or reversing hair discoloration |
| 08/16/2001 | WO2001058441A1 Method and compositions for treating an inflammatory disease |
| 08/16/2001 | WO2001058440A1 Remedies for degenerative arthritis |
| 08/16/2001 | WO2001058439A1 Low dose modafinil for enhancement of cognitive function |
| 08/16/2001 | WO2001058438A1 Ophthalmic use of alpha adrenergic blocking agents |
| 08/16/2001 | WO2001058437A1 Nerve growth factor activity potentiating agents |
| 08/16/2001 | WO2001058436A1 Antagonists for nicotinic acetylcholine receptor, which are containing borneol or camphor as an active ingredient |
| 08/16/2001 | WO2001058435A1 Autonomic controlling agents |
| 08/16/2001 | WO2001058434A2 Diagnostic and therapeutic compositions and methods for affecting tumor growth using oxygen mimetic agents |
| 08/16/2001 | WO2001058433A1 Timed pulsatile drug delivery systems |
| 08/16/2001 | WO2001058425A2 Pharmaceutical composition for pulmonary delivery |
| 08/16/2001 | WO2001058410A2 A method of treating colon cancer by administering apigenin, luteolin, diosmetin and crysin |
| 08/16/2001 | WO2001058351A1 Method for classifying and treating physiologic brain imbalances using quantitative eeg |
| 08/16/2001 | WO2001058283A1 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| 08/16/2001 | WO2001058241A2 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| 08/16/2001 | WO2001058240A2 Photodynamic therapy for treating conditions of the eye |
| 08/16/2001 | WO2001051047A8 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 08/16/2001 | WO2001023550A3 Pca3 messenger rna species in benign and malignant prostate tissues |
| 08/16/2001 | WO2001012201A8 Blood plasma replacement solution |
| 08/16/2001 | WO2001012180A3 Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce |
| 08/16/2001 | WO2001011024A3 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 08/16/2001 | WO2001010893A3 Il-16 antagonists |
| 08/16/2001 | WO2001010842A3 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 08/16/2001 | WO2001010429A3 Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions |
| 08/16/2001 | WO2001010413A3 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 08/16/2001 | WO2001010385A3 1,4-substituted 4,4-diaryl cyclohexanes |
| 08/16/2001 | WO2001010381A3 Methods for treating or preventing pain and anxiety |
| 08/16/2001 | WO2001010380A3 Benzanilides as potassium channel openers |
| 08/16/2001 | WO2001009115A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
| 08/16/2001 | WO2001009096A3 Potassium channel openers |
| 08/16/2001 | WO2001008688A3 Beta-carboline drug products |
| 08/16/2001 | WO2001007628A3 Human synthetases |
| 08/16/2001 | WO2001007595A3 Novel fibroblast growth factor and nucleic acids encoding same |
| 08/16/2001 | WO2001007435A3 N-(indolcarbonyl-)piperazin derivatives als 5-ht2a-receptor ligands |
| 08/16/2001 | WO2001007431A3 Benzothiophene derivatives |
| 08/16/2001 | WO2001007033A3 Neuroprotective pharmaceutical reparations comprising p-fluoroselegiline |
| 08/16/2001 | WO2001006989A3 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 08/16/2001 | WO2001000195A3 Pharmaceutical compositions comprising nitric synthase inhibitors for treating decrease blood pressure |
| 08/16/2001 | WO2001000190A3 Hyaluronic acid derivatives for the prevention and treatment of cutaneous scars |
| 08/16/2001 | WO2000078396A3 Topical ophthalmic mast cell stabilizers for treating allergic eye diseases |
| 08/16/2001 | WO2000076551A3 Method for producing an injectable medicament preparation |
| 08/16/2001 | WO2000076500A8 Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| 08/16/2001 | WO2000067742A3 Use of gaba analogues for the modulation of substance p |
| 08/16/2001 | WO2000066106A3 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 08/16/2001 | WO2000061128A3 R-hydroxynefazodone |
| 08/16/2001 | WO2000059487A3 Flupirtine in the treatment of fibromyalgia and related conditions |
| 08/16/2001 | WO2000058506A3 Susceptibility to psoriasis |
| 08/16/2001 | WO2000057866A3 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 08/16/2001 | WO2000056302A3 Vanadium (iv) complexes containing catacholate ligand and having spermicidal activity |
| 08/16/2001 | WO2000047551A3 Inhibitors of aspartyl protease |
| 08/16/2001 | WO2000044443A3 Intra-pericardial delivery of anti-microtubule agents |
| 08/16/2001 | WO2000041531A3 Serine protease inhibitors |
| 08/16/2001 | WO2000015212A3 Antifungal activity of dicationic molecules |
| 08/16/2001 | WO1999064046A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors |
| 08/16/2001 | US20010014749 Agonists or antagonists for genomic or high speed celluar responses; glandular or endocrine disorders |
| 08/16/2001 | US20010014741 Antiallergens, antihistamines, bronchodilator |
| 08/16/2001 | US20010014740 Method of producing heterocyclic derivatives |
| 08/16/2001 | US20010014737 Antiinflammatory agents, cardiovascualr disorders, osteoporosis, anticancer agents |
| 08/16/2001 | US20010014699 Malaria, schistosomiasis |
| 08/16/2001 | US20010014698 Method for preventing and treating alcoholism |
| 08/16/2001 | US20010014696 Therapeutic compositions (II) |
| 08/16/2001 | US20010014695 Therapy for degradation diseases; oxidation resistance |
| 08/16/2001 | US20010014694 Hypotensive agents, stroke, vision defects, kidney disorders |
| 08/16/2001 | US20010014693 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 08/16/2001 | US20010014691 Nervous system disorders |
| 08/16/2001 | US20010014690 Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action |
| 08/16/2001 | US20010014689 Nervous system disorders |
| 08/16/2001 | US20010014685 Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| 08/16/2001 | US20010014684 Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| 08/16/2001 | US20010014683 Analgesics; side effect reduction |
| 08/16/2001 | US20010014679 Animal growth regulator; controlling cell differentiation, gene expression, glucose metabolism, protein metabolism |
| 08/16/2001 | US20010014678 Using mixture of a nicotine receptor antagonist and antidepressant and,or anxiolytic agent |
| 08/16/2001 | US20010014677 Restenosis, kidney diseases, lung diseases |
| 08/16/2001 | US20010014676 For mammals; mixture with drug |
| 08/16/2001 | US20010014675 Anticarcer agent |
| 08/16/2001 | US20010014671 Treatment of osteoarthritis by administering poly-N-acetyl-D-glucosamine |
| 08/16/2001 | US20010014670 Treating chlamydia infections of central nervous system in mammals/humans not exhibiting symptoms of multiple sclerosis or meningoencephalitis via administering antibiotic; ELISA kits |
| 08/16/2001 | US20010014669 Method for preventing or treating elevated blood lipid level-related diseases by administering rutin and quercetin |
| 08/16/2001 | US20010014664 Viscosity; biodegradability; fibroblast growth factor |
| 08/16/2001 | US20010014663 Treatment of allograft rejection with anti-angiogenic agents |
| 08/16/2001 | US20010014454 Novel metal complexes |
| 08/16/2001 | US20010014453 Such as N,N-bis(2-trimethoxysilylpropyl)ethanolamine; for silanation of surfaces such as glass and subsequent immobilization of nucleic acids and polypeptides |
| 08/16/2001 | US20010014442 Containing tyrosine and,or phenylalanine |
| 08/16/2001 | US20010014357 Citrus peel extract as inhibitor of ACYL coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 08/16/2001 | US20010014354 Stability |
| 08/16/2001 | US20010014353 Directly compressible high load acetaminophen formulations |
| 08/16/2001 | US20010014352 Compressed tablet formulation |
| 08/16/2001 | US20010014349 Consists of a local anesthetics and the antipruritic agent such as lidocaine and an alcohol (c1-c4) or acetone which is water miscible, and solubilizes the anesthetic and is volatile and devoid any compound other than water |
| 08/16/2001 | US20010014342 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
| 08/16/2001 | US20010014339 Forming a water in oil emulsion comprising a solution containing a water-soluble 2-piprazinone-1-acetic acid derivative and arganine as intergrin antagonist, a solvent, abiodegradable polymer, and fat and oil, removing the solvent |
| 08/16/2001 | US20010014338 Intermediate release nicotinic acid formulation having a dissolution curve similarity fit factor of about 79, and in in vitro dissolution profile in deionized water at about 100rpm; time release agents |
| 08/16/2001 | US20010014329 Methods of identifying modulators of kinases responsive to stress |
| 08/16/2001 | US20010014328 A multispecific binding molecule, comprising a first binding determinant which binds an Fc alpha receptor is not blocked by human immunoglobin A and a second binding determinant binds target cancer cell antigen |